← IONIS PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $346.6m | $507.7m | $599.7m | $1.1b | $729.3m | $810.5m | $587.4m | $787.6m | $705.1m | $943.7m | |
| Cost of Revenue | $260.0m | $380.7m | $1.8m | $4.4m | $11.9m | $10.8m | $14.1m | $9.1m | $11.2m | $15.9m | |
| Gross Profit (Calculated) (derived) | $86.7m | $126.9m | $597.9m | $1.1b | $717.3m | $799.6m | $573.3m | $778.5m | $693.9m | $927.8m | |
| Operating Expenses | $392.9m | $483.1m | $661.0m | — | — | — | — | — | — | — | |
| Operating Income (Loss) | ($46.3m) | $24.5m | ($61.4m) | $365.9m | ($172.1m) | ($30.2m) | ($410.2m) | ($353.7m) | ($475.1m) | ($381.7m) | |
| Additional Financial Items | |||||||||||
| Amortization of Intangible Assets | — | — | $1.8m | $1.9m | $2.1m | $2.4m | $2.4m | $2.6m | $2.3m | $2.4m | |
| Gain (Loss) on Investments | $56k | — | ($210k) | $192k | $16.5m | $10.1m | ($7.3m) | ($1.9m) | ($2.9m) | $10.2m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | ($11.8m) | ($69.6m) | $344.3m | ($172.7m) | ($30.0m) | ($258.5m) | ($334.7m) | ($460.7m) | ($381.2m) | |
| Realized Investment Gains (Losses) | — | — | — | — | — | $1.1m | ($224k) | ($1.6m) | ($2.9m) | $9.3m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($83.6m) | — | — | — | — | ($29.1m) | ($258.0m) | ($334.0m) | ($460.1m) | ($379.6m) | |
| Investment Income, Net | $5.4m | $7.8m | $30.2m | $52.2m | $30.6m | $10.0m | $25.3m | $89.0m | $107.0m | $97.8m | |
| Net Income (Loss) Attributable to Parent | ($86.6m) | ($6.0m) | $273.7m | $294.1m | ($451.3m) | ($28.6m) | ($269.7m) | ($366.3m) | ($453.9m) | ($381.4m) | |
| Net Income (Loss) Available to Common Stockholders, Basic | — | $9.7m | $276.9m | $296.6m | ($451.5m) | — | — | — | — | — | |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | ($11.3m) | ($58.8m) | $9.1m | ($35.5m) | $0 | $0 | — | — | — | |
| Earnings Per Share, Basic | — | $0.08 | $2.09 | $2.12 | ($3.23) | ($0.20) | ($1.90) | ($2.56) | ($3.04) | ($2.38) | |
| Earnings Per Share, Diluted | — | $0.08 | $2.07 | $2.08 | ($3.23) | ($0.20) | ($1.90) | ($2.56) | ($3.04) | ($2.38) | |
| Weighted Average Number of Shares Outstanding, Basic | — | 124.0m | 132.3m | 140.0m | 139.6m | 141.0m | 141.8m | 143.2m | 149.5m | 160.0m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | 126.1m | 134.1m | 142.9m | 139.6m | 141.0m | 141.8m | 143.2m | 149.5m | 160.0m | |
| Research and Development Expense | $340.4m | $372.5m | $411.9m | $461.5m | $531.0m | $638.2m | — | — | — | $915.6m | |
| General and Administrative Expense | $48.6m | — | — | — | — | — | — | — | — | — | |
| Selling, General and Administrative Expense | $48.6m | $108.5m | $244.6m | $286.6m | $354.3m | $186.3m | $150.3m | $232.6m | $267.5m | $393.9m | |
| Other Nonoperating Income (Expense) | — | — | ($182k) | ($686k) | ($62k) | ($1.1m) | ($7.3m) | $14.3m | $1.3m | ($15.4m) | |
| Costs and Expenses | — | — | — | $756.7m | $901.3m | $840.6m | $997.6m | $1.1b | $1.2b | $1.3b | |
| Current Income Tax Expense (Benefit) | $2.9m | ($6.0m) | ($630k) | $50.6m | $3.5m | ($551k) | $11.7m | $32.3m | ($6.2m) | $1.8m | |
| Interest Expense | $38.8m | $44.8m | $44.8m | $48.8m | $45.0m | $9.3m | $8.1m | $12.7m | $17.0m | $17.3m | |
| Operating Lease, Expense | — | — | — | $3.6m | $3.7m | $3.4m | $8.3m | $23.1m | $23.2m | $26.0m | |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | — | — | — | — | — | — | — | — | $131.0m | $135.7m | |
| Income Tax Expense (Benefit) | $2.9m | ($6.0m) | ($291.1m) | $43.5m | $316.7m | ($551k) | $11.7m | $32.3m | ($6.2m) | $1.8m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.